As reported in 1994, the original SOD1-G93A strain, designated G1, expressed approximately 18 copies of human SOD1, randomly inserted into the genome (Gurney et al., 1994). An unequal crossover event ...

Background Sensory Stimulation Systems, and GENUS, refer to a noninvasive procedure, i.e., a "digital therapeutic," being developed by Cognito Therapeutics. The company developed a wearable GammaSense ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the brain: ...

Series - Clinical Trials on Alzheimer's Disease 2018: Part 1 of 10: Bump in the Road or Disaster? BACE Inhibitors Worsen Cognition Part 2 of 10: Second Look at BAN2401 Data Still Positive, Despite ...

Including nearly 20,000 participants, the largest study on amyloid prevalence to date estimates that a third of cognitively normal people older than 70 have amyloid building up in their brains.

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

Current diagnostic options for PD include DaTscan SPECT to assess dopamine transporter activity, the Syn-One test to detect α-synuclein aggregates in a skin biopsy, or the SYNTap α-synuclein seed ...

There was a new feeling in the air at the 12th Clinical Trials on Alzheimer’s Disease conference. It felt good: After decades of failure, the field might finally be turning a corner. The renewed ...

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...

A lot can happen in a year. At the 2017 Alzheimer’s Association International Conference in London, Randall Bateman ’s team at Washington University in St. Louis wowed the crowd with a blood assay for ...